174 related articles for article (PubMed ID: 34572480)
1. The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis.
Ye LF; Ji XM; Ren C; Wang ZQ; Lin CP; Chen DL; Cai YQ; Jin Y; Qiu MZ; Du ZM; Xi SY; Zhang DS; Wang F; Wang FH; Xu RH; Li YH; Wang DS
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572480
[TBL] [Abstract][Full Text] [Related]
2. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
3. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
4. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
[TBL] [Abstract][Full Text] [Related]
5. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
6. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments.
Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E
Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693
[TBL] [Abstract][Full Text] [Related]
7. Metastatic pattern is a prognostic factor in BRAF
Ji J; Sandhu J; Wang C; Fakih M
Cancer Treat Res Commun; 2023; 35():100714. PubMed ID: 37126990
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.
Javed S; Benoist S; Devos P; Truant S; Guimbaud R; Lièvre A; Sefrioui D; Cohen R; Artru P; Dupré A; Bachet JB; de la Fouchardière C; Ploquin A; Turpin A
World J Surg Oncol; 2022 Apr; 20(1):131. PubMed ID: 35461290
[TBL] [Abstract][Full Text] [Related]
10.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
11. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
12. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer.
Prasanna T; Wong R; Price T; Shapiro J; Tie J; Wong HL; Nott L; Roder D; Lee M; Kosmider S; Jalali A; Burge M; Padbury R; Maddern G; Carruthers S; Moore J; Sorich M; Karapetis CS; Gibbs P; Yip D
Curr Probl Cancer; 2021 Feb; 45(1):100637. PubMed ID: 32826083
[TBL] [Abstract][Full Text] [Related]
13. Population-based Screening for
Chu JE; Johnson B; Kugathasan L; Morris VK; Raghav K; Swanson L; Lim HJ; Renouf DJ; Gill S; Wolber R; Karsan A; Kopetz S; Schaeffer DF; Loree JM
Clin Cancer Res; 2020 Sep; 26(17):4599-4605. PubMed ID: 32571791
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
15. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
16. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
Atreya CE; Greene C; McWhirter RM; Ikram NS; Allen IE; Van Loon K; Venook AP; Yeh BM; Behr SC
J Natl Compr Canc Netw; 2016 Dec; 14(12):1536-1543. PubMed ID: 27956538
[TBL] [Abstract][Full Text] [Related]
17. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tural D; Batur S; Erdamar S; Akar E; Kepil N; Mandel NM; Serdengeçti S
Tumour Biol; 2014 Feb; 35(2):1041-9. PubMed ID: 23996432
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
Kobayashi S; Takahashi S; Nomura S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N; Taniguchi H; Yoshino T
Cancer Med; 2021 Oct; 10(20):6998-7011. PubMed ID: 34535965
[TBL] [Abstract][Full Text] [Related]
19. Class 1, 2, and 3
Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
[TBL] [Abstract][Full Text] [Related]
20. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
